New drug duo tested for tough bladder cancers
NCT ID NCT06263153
Summary
This study is testing a combination of two drugs, futibatinib and durvalumab, given before surgery to remove the bladder. It is for patients with muscle-invasive bladder cancer who cannot receive the usual chemotherapy due to other health problems like kidney issues or heart failure. The goal is to see if this drug combination can shrink or eliminate the cancer before surgery, potentially improving outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Taussig Cancer Center
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Michigan Comprehensive Cancer Center
WITHDRAWNAnn Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.